S-Adenosylhomocysteine: a better indicator of vascular disease than homocysteine?

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Metabolomics

Background:

• Elevated plasma total homocysteine is a known risk factor for vascular disease, but the underlying pathophysiology remains unclear.
• S-adenosylhomocysteine (AdoHcy) is the metabolic precursor to homocysteine and is present in plasma at much lower concentrations, posing measurement challenges.
• Traditional methods for AdoHcy measurement are complex and time-consuming, limiting its use in large-scale studies.

Purpose of the Study:

• To introduce a rapid immunoassay for measuring plasma AdoHcy.
• To highlight the advantages of plasma AdoHcy measurement over plasma homocysteine for vascular disease risk assessment.
• To facilitate broader clinical and research applications of AdoHcy as a biomarker.

Main Methods:

• Development and validation of a rapid immunoassay for human plasma S-adenosylhomocysteine (AdoHcy).
• Comparison of AdoHcy and homocysteine levels in patient and control groups.
• Evaluation of AdoHcy's sensitivity as a vascular disease indicator.

Main Results:

• A novel, rapid immunoassay for plasma AdoHcy is now available for general use.
• Plasma AdoHcy measurement shows a smaller overlap between control and patient values compared to homocysteine.
• Higher plasma AdoHcy concentrations are a more sensitive indicator of vascular disease than elevated homocysteine levels.

Conclusions:

• Plasma AdoHcy measurement is a more sensitive biomarker for vascular disease risk.
• The new immunoassay simplifies AdoHcy detection, enabling wider clinical application.
• Understanding AdoHcy's role in methyltransferase inhibition provides a mechanistic link to vascular pathophysiology.